Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.15, delivering a surprise of 66.67%.Over the last four quarters, the company has sur ...

First Quarter 2025 Financial Results May 6, 2025 Agenda and Speakers Rob Claypoole President and Chief Executive Officer Update on Business and 2025 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q1 2025 Results 2025 Financial Guidance Forward Looking Statements and Use of Estimates Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchang ...

Bioventus (BVS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Day and welcome to the BioVentis First Quarter twenty twenty five Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Mr. Dave Crawford. Please go ahead, sir. Speaker1 Thanks, Chuck, and good morning, everybody, and thanks for joining us. It's my pleasure to welcome you to the BioVentis twenty twenty five first quarter earnings confere ...

Exhibit 99.1 Bioventus Reports First Quarter Financial Results DURHAM, NC – May 6, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025. "Our Bioventus team delivered solid results to start the year and we are making substantial progress with executing our strategic plan," said Rob Claypoole, Bioventus President and Chief Executive Officer. "We remain well positioned t ...

Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year periodNon-GAAP earnings* of $0.08 per share increased 33%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results ...

DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 ...

The U.S. healthcare sector is currently navigating a complex landscape characterized by technological innovation, policy shifts, financial pressures and evolving consumer expectations. While artificial intelligence (AI) is being increasingly integrated into healthcare, especially in areas like medical imaging and diagnostics, the biotech sector is experiencing significant challenges due to policy uncertainties and budget cuts under the Trump administration.Healthcare has lagged the S&P 500 over the past two ...

This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.' In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's ...

Bioventus (BVS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors ...

Bioventus (BVS) Q4 2024 Earnings Call March 11, 2025 04:23 PM ET Company Participants Dave Crawford - VP - IR & TreasurerRobert Claypoole - CEOMark Singleton - Senior VP & CFOCaitlin Cronin - Director Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareLilia-Celine Lozada - Analyst Operator Good morning, and welcome to the BioVentis Fourth Quarter twenty twenty four Earnings Conference Call. All participants will be in listen only mode. After today's presentation, t ...